{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Garmpis D"],"pubmed_abstract":["<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced melanoma, yet predictive biomarkers for treatment response and survival remain limited. Immune-related adverse events (irAEs) are frequent during ICI therapy and have been associated with improved outcomes, while baseline inflammatory markers-such as C-Reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR)-often predict poor prognosis. However, no study to date has systematically integrated irAE characteristics and blood-based inflammation profiles to evaluate their combined prognostic value across different therapy lines.<h4>Methods</h4>We retrospectively analyzed 231 patients with unresectable stage IIIC-IV melanoma treated with PD-1-based ICIs at the University Hospital Cologne (2015-2021)"],"journal":["Frontiers in immunology"],"pagination":["1683533"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12521244"],"repository":["biostudies-literature"],"pubmed_title":["Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy."],"pmcid":["PMC12521244"],"pubmed_authors":["Hidalgo-Gadea G","Franklin C","Garmpis D","Mauch C","Tietze JK"],"additional_accession":[]},"is_claimable":false,"name":"Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy.","description":"<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced melanoma, yet predictive biomarkers for treatment response and survival remain limited. Immune-related adverse events (irAEs) are frequent during ICI therapy and have been associated with improved outcomes, while baseline inflammatory markers-such as C-Reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR)-often predict poor prognosis. However, no study to date has systematically integrated irAE characteristics and blood-based inflammation profiles to evaluate their combined prognostic value across different therapy lines.<h4>Methods</h4>We retrospectively analyzed 231 patients with unresectable stage IIIC-IV melanoma treated with PD-1-based ICIs at the University Hospital Cologne (2015-2021)","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-04T11:44:01.56Z","creation":"2026-05-08T03:11:08.003Z"},"accession":"S-EPMC12521244","cross_references":{"pubmed":["41103410"],"doi":["10.3389/fimmu.2025.1683533"]}}